Advances in antibody-drug conjugates in the treatment of urothelial carcinoma
10.3760/cma.j.cn112330-20220513-00282
- VernacularTitle:抗体偶联药物治疗转移性尿路上皮癌的临床研究进展
- Author:
Bonan FAN
1
;
Lingwu CHEN
Author Information
1. 中山大学中山医学院临床医学系，广州 510000
- Keywords:
Urothelial carcinoma;
Antibody-drug conjugate;
Development of studies
- From:
Chinese Journal of Urology
2023;44(3):230-233
- CountryChina
- Language:Chinese
-
Abstract:
At present, antibody-drug conjugate is the focus of the research and development of new anticancer drugs. Three antibody-drug conjugates have been approved for the treatment of urothelial carcinoma, including Enfortumab Vedotin (Nectin-4 antibody-MMAE conjugate), Sacitumab Govitecan (Trop-2 antibody-SN-38 conjugate), and Disitamab Vedotin (HER2 antibody-MMAE conjugate) significantly improved the prognosis in patients with advanced disease, revolutionizing the treatment landscape of urothelial carcinoma. In addition, a number of studies that focus on combination of antibody-drug conjugate with targeted therapy, immunocheckpoint inhibitors is also under way. This article reviews the recent clinical development of antibody-drug conjugate in the treatment of urothelial carcinoma in recent years.
